Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase
            II
            , open‐label trial

M. Seyger; W. Abramovits; M. Liljedahl; M.N. Hoejen; J. Teng

doi:10.1111/jdv.16233

Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II , open‐label trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16233 ◽

2020 ◽

Vol 34 (9) ◽

pp. 2026-2034 ◽

Cited By ~ 2

Author(s):

M. Seyger ◽

W. Abramovits ◽

M. Liljedahl ◽

M.N. Hoejen ◽

J. Teng

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Betamethasone Dipropionate ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Open Label ◽

Safety And Efficacy ◽

Adolescent Patients ◽

Dose Combination ◽

Open Label Trial

Download Full-text

Safety and efficacy of topical, fixed‐dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16077 ◽

2020 ◽

Vol 34 (5) ◽

pp. 1098-1104 ◽

Cited By ~ 1

Author(s):

L.F. Eichenfield ◽

D. Marcoux ◽

M. Kurvits ◽

M. Liljedahl

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Safety And Efficacy ◽

Adolescent Patients ◽

Dose Combination

Download Full-text

Efficacy of fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in adolescent patients with psoriasis: Results from a phase 2 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.742 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB201

Keyword(s):

Betamethasone Dipropionate ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 2 ◽

Phase 2 Trial ◽

Adolescent Patients ◽

Dose Combination

Download Full-text

Safety of fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in adolescent patients with psoriasis: Results from a phase 2 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.1181 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB271

Keyword(s):

Betamethasone Dipropionate ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 2 ◽

Phase 2 Trial ◽

Adolescent Patients ◽

Dose Combination

Download Full-text

Open-label trial of three dosage regimens of fixed-dose combination of artemisinin and naphthoquine for treating uncomplicated falciparum malaria in calabar, Nigeria

Malaria Journal ◽

10.1186/1475-2875-11-413 ◽

2012 ◽

Vol 11 (1) ◽

Cited By ~ 9

Author(s):

Martin M Meremikwu ◽

Friday Odey ◽

Chioma Oringanje ◽

Angela Oyo-ita ◽

Emmanuel Effa ◽

...

Keyword(s):

Falciparum Malaria ◽

Fixed Dose Combination ◽

Uncomplicated Falciparum Malaria ◽

Fixed Dose ◽

Open Label ◽

Dosage Regimens ◽

Dose Combination ◽

Open Label Trial

Download Full-text

Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication

Expert Opinion on Pharmacotherapy ◽

10.1517/14656560802707937 ◽

2009 ◽

Vol 10 (3) ◽

pp. 345-352 ◽

Cited By ~ 4

Author(s):

Steen Neldam ◽

Colin Edwards

Keyword(s):

Antihypertensive Medication ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Open Label ◽

Safety And Efficacy ◽

Dose Combination

Download Full-text

16830 Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.835 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB187

Author(s):

Mark Lebwohl ◽

Jean Philippe LACOUR ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie Mørch ◽

...

Keyword(s):

Treatment Period ◽

Betamethasone Dipropionate ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Open Label ◽

Phase Iii Trial ◽

Proactive Management ◽

Dose Combination

Download Full-text

Faculty Opinions recommendation of Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725431366.793505980 ◽

2015 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C ◽

Japanese Patients ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination ◽

Previously Treated

Download Full-text

Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fixed-Dose Combination for Treatment of HIV in Adolescents and Children: Week 48 Results from an Open-Label, Multicentre, Phase 2/3 Paediatric Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3666840 ◽

2020 ◽

Author(s):

Aditya H. Gaur ◽

Mark F. Cotton ◽

Carina A. Rodriguez ◽

Eric J. McGrath ◽

Elizabeth Hellstrom ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Paediatric Trial ◽

Dose Combination ◽

Tenofovir Alafenamide

Download Full-text

Pharmacokinetics of atorvastatin and sustained-release metformin fixed-dose combination tablets: two randomized, open-label, 2-way crossover studies in healthy male subjects under fed conditions

Translational and Clinical Pharmacology ◽

10.12793/tcp.2017.25.4.190 ◽

2017 ◽

Vol 25 (4) ◽

pp. 190

Author(s):

Young-Kyung Choi ◽

Sung-Eun Park ◽

Eun-Young Kim ◽

Hyo Ju Park ◽

Eun-Ji Kim ◽

...

Keyword(s):

Sustained Release ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Healthy Male ◽

Open Label ◽

Crossover Studies ◽

Dose Combination ◽

Male Subjects

Download Full-text

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3

AIDS Research and Therapy ◽

10.1186/1742-6405-4-6 ◽

2007 ◽

Vol 4 (1) ◽

pp. 6 ◽

Cited By ~ 6

Author(s):

Weerawat Manosuthi ◽

Sukanya Chimsuntorn ◽

Sirirat Likanonsakul ◽

Somnuek Sungkanuparph

Keyword(s):

Antiretroviral Therapy ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Safety And Efficacy ◽

Dose Combination

Download Full-text